Relation Between Soluble Intercellular Adhesion Molecule-1, Statin Therapy, and Long-Term Risk of Clinical Cardiovascular Events in Patients With Previous Acute Coronary Syndrome (from PROVE IT-TIMI 22)

American Journal of Cardiology

Volumn 98, Issue 7, 2006, Pages 861-865

  Ray, Kausik K ^a   Morrow, David A ^a   Shui, Amy ^a   Rifai, Nader ^b   Cannon, Christopher P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN;

ACUTE CORONARY SYNDROME; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETES MELLITUS; ENDOTHELIUM CELL; FEMALE; HEART INFARCTION; HOSPITALIZATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SMOKING;

ANGINA, UNSTABLE; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERCELLULAR ADHESION MOLECULE-1; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; RISK ASSESSMENT; RISK FACTORS;

EID: 33748747486     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.04.024     Document Type: Article

References (22)

1. Fassbender K., Kaptur S., Becker P., Groschl J., and Hennerici M. Adhesion molecules in tissue injury: kinetics of expression and shedding and association with cytokine release in humans. Clin Immunol Immunopathol 89 (1998) 54-60
2. Wyble C.W., Hynes K.L., Kuchibhotla J., Marcus B.C., Hallahan D., and Gewertz B.L. TNF-alpha and IL-1 upregulate membrane-bound and soluble E-selectin through a common pathway. J Surg Res 73 (1997) 107-112
3. Leeuwenberg J.F., Smeets E.F., Neefjes J.J., Shaffer M.A., Cinek T., Jeunhomme T.M., Ahern T.J., and Buurman W.A. E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology 77 (1992) 543-549
4. Mulvihill N., Foley J.B., Ghaisas N., Murphy R., Crean P., and Walsh M. Early temporal expression of soluble cellular adhesion molecules in patients with unstable angina and subendocardial myocardial infarction. Am J Cardiol 83 (1999) 1265-1267
5. Hwang S.J., Ballantyne C.M., Sharrett A.R., Smith L.C., Davis C.E., Gotto Jr. A.M., and Boerwinkle E. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 96 (1997) 4219-4225
6. Malik I., Danesh J., Whincup P., Bhatia V., Papacosta O., Walker M., Lennon L., Thomson A., and Haskard D. Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet 358 (2001) 971-976
7. Blankenberg S., Rupprecht H.J., Bickel C., Peetz D., Hafner G., Tiret L., and Meyer J. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 104 (2001) 1336-1342
8. Ray K.K., Cannon C.P., McCabe C.H., Cairns R., Tonkin A.M., Sacks F.M., Jackson G., and Braunwald E. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 46 (2005) 1405-1410
9. Cannon C.P., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., Belder R., Joyal S.V., Hill K.A., Pfeffer M.A., and Skene A.M. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
10. Ridker P.M., Cannon C.P., Morrow D., Rifai N., Rose L.M., McCabe C.H., Pfeffer M.A., Braunwald E., and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 (2005) 20-28
11. Ridker P.M., Morrow D.A., Rose L.M., Rifai N., Cannon C.P., and Braunwald E. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol 45 (2005) 1644-1648
12. Gimbrone Jr. M.A., Bevilacqua M.P., and Cybulsky M.I. Endothelial-dependent mechanisms of leukocyte adhesion in inflammation and atherosclerosis. Ann NY Acad Sci 598 (1990) 77-85
13. Johnson-Tidey R.R., McGregor J.L., Taylor P.R., and Poston R.N. Increase in the adhesion molecule P-selectin in endothelium overlying atherosclerotic plaques. Coexpression with intercellular adhesion molecule-1. Am J Pathol 144 (1994) 952-961
14. Naruko T., Ueda M., Haze K., van der Wal A.C., van der Loos C.M., Itoh A., Komatsu R., Ikura Y., Ogami M., Shimada Y., et al. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation 106 (2002) 2894-2900
15. Kennon S., Price C.P., Mills P.G., Ranjadayalan K., Cooper J., Clarke H., and Timmis A.D. The effect of aspirin on C-reactive protein as a marker of risk in unstable angina. J Am Coll Cardiol 37 (2001) 1266-1270
16. Feng D., Tracy R.P., Lipinska I., Murillo J., McKenna C., and Tofler G.H. Effect of short-term aspirin use on C-reactive protein. J Thromb Thrombolysis 9 (2000) 37-41
17. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., and Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336 (1997) 973-979
18. Chew D.P., Bhatt D.L., Robbins M.A., Mukherjee D., Roffi M., Schneider J.P., Topol E.J., and Ellis S.G. Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am J Cardiol 88 (2001) 672-674
19. Weitz-Schmidt G., Welzenbach K., Brinkmann V., Kamata T., Kallen J., Bruns C., Cottens S., Takada Y., and Hommel U. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 7 (2001) 687-692
20. Gill V., Doig C., Knight D., Love E., and Kubes P. Targeting adhesion molecules as a potential mechanism of action for intravenous immunoglobulin. Circulation 112 (2005) 2031-2039
21. Inoue T., Tsuzuki Y., Matsuzaki K., Matsunaga H., Miyazaki J., Hokari R., Okada Y., Kawaguchi A., Nagao S., Itoh K., et al. Blockade of PSGL-1 attenuates CD14+ monocytic cell recruitment in intestinal mucosa and ameliorates ileitis in SAMP1/Yit mice. J Leukoc Biol 77 (2005) 287-295
22. Van Assche G., and Rutgeerts P. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 288 suppl (2005) G169-G174